These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8708587)

  • 1. The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group.
    Johannesson M; Borgquist L; Jönsson B; Lindholm LH
    J Intern Med; 1996 Jul; 240(1):23-9. PubMed ID: 8708587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study.
    Lindholm LH; Ekbom T; Dash C; Isacsson A; Scherstén B
    J Intern Med; 1996 Jul; 240(1):13-22. PubMed ID: 8708586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of health care advice given in primary care on cardiovascular risk. CELL Study Group.
    Lindholm LH; Ekbom T; Dash C; Eriksson M; Tibblin G; Scherstén B
    BMJ; 1995 Apr; 310(6987):1105-9. PubMed ID: 7742677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advice.
    Lindgren P; Fahlstadius P; Hellenius ML; Jönsson B; de Faire U
    Prev Med; 2003 Apr; 36(4):403-9. PubMed ID: 12649048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men.
    Johannesson M; Agewall S; Hartford M; Hedner T; Fagerberg B
    J Intern Med; 1995 Jan; 237(1):19-26. PubMed ID: 7830026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
    Pharoah PD; Hollingworth W
    BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial.
    Osborn D; Burton A; Hunter R; Marston L; Atkins L; Barnes T; Blackburn R; Craig T; Gilbert H; Heinkel S; Holt R; King M; Michie S; Morris R; Morris S; Nazareth I; Omar R; Petersen I; Peveler R; Pinfold V; Walters K
    Lancet Psychiatry; 2018 Feb; 5(2):145-154. PubMed ID: 29396118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?
    Kristiansen IS; Eggen AE; Thelle DS
    BMJ; 1991 May; 302(6785):1119-22. PubMed ID: 1904286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for reducing coronary risk factors in primary care: which is most cost effective?
    Field K; Thorogood M; Silagy C; Normand C; O'Neill C; Muir J
    BMJ; 1995 Apr; 310(6987):1109-12. PubMed ID: 7742678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.